BMT group study day

The fifth educational meeting of the UK BMT Pharmacists’ Group took place at the UCLH Education Centre, London on the afternoon of Friday 12th July 2019.  Over 30 pharmacists from 22 different UK transplant centres attended.  Sponsorship was very kindly provided by Incyte, Jazz and Pfizer.  Topics presented included stem cell transplantation in lymphoma, challenges associated with diagnosing invasive fungal infections in haematology patients, feedback from the recent European Haematology Association (EHA) conference and the role of the clinical pharmacist in the management of CAR-T patients.  A full report is available here. You will need to log in to access.

It was fantastic to see so many haematology pharmacists at the meeting and we are aiming to hold our next educational meeting before the end of 2019.  Please keep an eye out for further details which will be posted on the group’s page on the BOPA website soon.

Nick Duncan and Simon Cheesman

Co-chairs, UK BMT Pharmacists’ Group

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article